Catherine Leblanc

PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS

PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN

NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND

PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS

Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use

Pyrazolyl derivatives useful as anti-cancer agents

Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Formylated N-heterocyclic derivatives as FGFR4 inhibitors

Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

Formylated N-heterocyclic derivatives as FGFR4 inhibitors

Pharmaceutical combinations

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

IP receptor agonist heterocyclic compounds

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases

Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists

IP receptor agonist heterocyclic compounds

IP receptor agonist heterocyclic compounds

Substituted pyrido[2,3-B]pyrazines as IP receptor agonists

IP receptor agonist heterocyclic compounds

Pyrrolopyridine derivatives and their use as CRTH2 antagonists

Pyrrolopyridine derivatives and their use as CRTH2 antagonists

Substituted pyrrolo[2,3-B]pyrazine compounds and their use